Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NuVasive MAGEC Devices To Return To US Market Despite Safety Concerns

Executive Summary

The FDA said the benefits of the devices, which are used to prevent spinal deformity in children with thoracic insufficiency syndrome, outweigh their known risks.

You may also be interested in...



NuVasive Recalls Orthopedics Implants Over Biocompatibility Concerns

The US FDA says the company has voluntarily issued a recall for Precice metal implants after reports of adverse events that could be related to the design of the product or biocompatibility issues.

Warning Letter Close-Outs – July 2021

The resolution of a May 2020 warning letter to a breast implant manufacturer accounted for the only device-related close-out latter issued this month.

Intuitive Fights Da Vinci Surgical Robot Monopoly Claims

Intuitive Surgical is facing multiple antitrust suits that say the company took advantage of its dominant market position by demanding hospitals come to it for expensive repairs and replacements.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel